The Digital Source For China's Tech Innovation Since 2000

Monoclonal antibody treatments have many challenges – Narval is fixing them

September 20, 2023
Source: techcrunch.com techcrunch.com
News Snapshot:
Monoclonal antibodies are the building blocks of some of the most important medical treatments in the world. But they have limitations. For example, the large size of the molecules mean monoclonal antibody treatments usually need to be injected — even for eye conditions. Narval CEO Jose Luis Nuno describes the first time he saw a patient get injected in the eye to treat diabetic retinopathy, a condition that can lead to blindness. “It costs $2,000 every month, you need to get one per month, so it’s very expensive, very difficult and of course painful to be injected there,” he said....
Go To Original Source →
Tags: AI | applications | Biotech | CEO | China | development | drug | drugs | European | European Union | Founder | German | healthcare | India | infrastructure | IT | library | logistics | manufacture | manufacturing | medical | medicine | Mexico | partnership | pharmaceutical

Other Related News:

Russia’s Victory Day parade begins, marking the 80th anniversary of the defeat of Nazi Germany

May 9, 2025

Genesis to tackle electric, plug-in hybrid BMW, Benz SUVs with new range-extender

May 9, 2025

Ban this foreign filth! Can cinema really threaten national security?

May 9, 2025

The Irish companies doing business in China: ‘The revenue potential for us is €300 million’

May 9, 2025

Scientists Have a Radical Plan to Grab a Sample of Venus's Toxic Atmosphere

May 9, 2025

UK-US pact neither a free-trade agreement nor broad trade deal of Brexiteer dreams

May 9, 2025

German defense firm partners with Iceye to build SAR satellites

May 9, 2025

The US is reportedly encouraging countries to adopt Musk’s Starlink in tariff trade talks

May 9, 2025

India-UK free trade agreement to take effect more than three months later, UK’s carbon tax deferred

May 9, 2025
  • Contact Us
  • About Us
  • Corrections and Disclosure
  • Privacy Policy
  • Terms & Conditions
  • Contact Us
  • About Us
  • Corrections and Disclosure
  • Privacy Policy
  • Terms & Conditions
© 2025 ChinaTechNews.com. A Service of Asia Media Network.
Twitter